COVID-19 Active Research Experience (CARE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04368065 |
Recruitment Status :
Recruiting
First Posted : April 29, 2020
Last Update Posted : July 12, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
COVID-19 |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 100000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 12 Months |
Official Title: | Registry to Study Factors That May Impact COVID-19 Occurrence and Severity |
Actual Study Start Date : | April 2, 2020 |
Estimated Primary Completion Date : | December 31, 2022 |
Estimated Study Completion Date : | June 1, 2023 |

- COVID-19 symptom occurrence and severity [ Time Frame: 12 months ]Occurrence and severity of potential COVID-19 symptoms as reported by participants in the survey
- COVID-19 treatments [ Time Frame: 12 months ]Prescription treatments for COVID-19 as reported by participants in the survey
- COVID-19 risk factors [ Time Frame: 12 months ]Assess potential role of comorbidities and concomitant medications on COVID-19 occurrence and severity
- Occurrence and severity of COVID-19 infection after vaccination [ Time Frame: 12 months ]Occurrence and severity of COVID-19 infection as reported by participants after SARS-CoV-2 vaccine
- Occurrence of medically attended events after vaccination [ Time Frame: 1 month ]Occurrence of medically attended events as reported by participants after after SARS-CoV-2 vaccine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Adult (18 years or older)
- Currently living in the US or UK
- Have regular access to a computer, smartphone or tablet and sufficient internet to support registry demands (note: this registry is designed to operate well even in regions with low bandwidth)
- Willing and able to provide informed consent
- Willing and able to follow the procedures of the study
Participants must also meet at least one of the following conditions:
- Have COVID-19 or COVID-19 like symptoms
- Received a COVID-19 vaccine
- Potential exposure to COVID-19
Exclusion Criteria:
- Unable to provide informed consent
- Unable to perform the requested study tasks and unable or unwilling to assign a proxy informant to complete the tasks

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04368065
Contact: Tom Kwon | +1 917 328 4635 | tkwon@us.imshealth.com |
United States, Massachusetts | |
IQVIA | Recruiting |
Cambridge, Massachusetts, United States, 02139 | |
Contact: Nancy Dreyer CAREproject@iqvia.com | |
Principal Investigator: Nancy Dreyer, PhD, MPH | |
United Kingdom | |
IQVIA | Recruiting |
London, United Kingdom | |
Contact: Nancy Dreyer CAREproject@iqvia.com |
Principal Investigator: | Nancy Dreyer, PhD, MPH | Iqvia Pty Ltd |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Iqvia Pty Ltd |
ClinicalTrials.gov Identifier: | NCT04368065 |
Other Study ID Numbers: |
IQVIA_COVIDREGISTRY_2020 |
First Posted: | April 29, 2020 Key Record Dates |
Last Update Posted: | July 12, 2021 |
Last Verified: | July 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | It is anticipated that external researchers may want to leverage these data for public health and life sciences research. The intent is to provide limited data access to qualified researchers for research that has gone through a review process. |
Supporting Materials: |
Study Protocol |
Time Frame: | Data will be available during conduct of the study and two years following study completion. |
Access Criteria: | Qualified researchers that have undergone a review process may submit requests to the IQVIA Registry Data Governance Committee (DGC) requesting approval and access for specific research purposes. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |